(Ecofin Agency) – A global study called ” of last minute On the BNT162b2, potential most promising vaccine of the American drug company Pfizer, was launched Monday July 27, reports Reuters.
The clinical trial promoted by the German biotechnology company BioNTech and its partner Pfizer will cover around 120 sites worldwide and could affect up to 36,000 people, in regions heavily affected by Covid-19.
Specifically, patients will each receive two doses of the manufacturer’s vaccine to strengthen their immunity. The first 100 million doses should therefore allow about 50 million people to be vaccinated.
« The launch of the Phase 2/3 trial is a major step in our progress towards providing a potential vaccine to help fight the current COVID-19 pandemic According to Kathrin Jansen, head of vaccine research and development at Pfizer.
If the study proves conclusive, it will allow the development of the 1is approved messenger RNA (mRNA) vaccine.
Faced with the pandemic which has claimed nearly 650,000 lives worldwide and paralyzed economies, more than 150 vaccines are being developed.